



BLA 103979/S-5306

SUPPLEMENT APPROVAL

Genzyme Corporation
Attention: Rebecca Berger
Associate Director, Global Regulatory Affairs, CMC Biologics
Sanofi Genzyme, One Research Drive
Westborough, MA 01581

Dear Ms. Berger:

Please refer to your Supplemental Biologics License Application (sBLA) dated and received May 17, 2019, submitted under section 351(a) of the Public Health Service Act for Fabrazyme (agalsidase beta) (agalsidase beta) injection, 5 mg and 35 mg.

This “Changes Being Effected” supplemental biologics license application updates the packaging components, carton and container label for Fabrazyme 5 and 35 mg strength.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the prescribing information) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your May 17, 2019, submission containing final printed carton and container labels.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Melinda Bauerlien, Senior Regulatory Business Process Manager, at (301) 796 - 0906.

Sincerely,

{See appended electronic signature page}

Gibbes Johnson, Ph.D.
Director
Division of Biotechnology Review and Research IV
Office of Biotechnology Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:

Carton and Container Labeling



Gibbes
Johnson

Digitally signed by Gibbes Johnson

Date: 11/01/2019 11:21:26AM

GUID: 508da6da00026559efc8cb7b82db48f8